Hematology-Oncology Fellowship
322
Peer-Reviewed Publications in 2023
64K+
Patient Encounters
92
Active Clinical Trials
About the Fellowship
Curriculum
The Houston Methodist Hematology-Oncology Fellowship is an ACGME-accredited program designed to shape future leaders in hematology and oncology through comprehensive education and intensive training in clinical practice and research. The three-year program fully integrates the ACGME core competencies and milestones through a required set of rotations, a didactic curriculum and elective rotations designed to broaden the base of knowledge. Located in the Texas Medical Center, we have exposure to a diverse patient population. All training takes place within the Houston Methodist Hospital ranked as number one hospital in Texas and connected facilities in the Texas Medical Center.
We recognize that next generations of competent hematologists and oncologists need to be fortified with diverse range of knowledge and competencies, including cancer prevention, clinical cancer genetics, health policy, cost-effective evidence-based patient care, along with translational and clinical research experience. Our fellows are given the structure and supervision required to ensure that each are well-trained, competent hematologists and oncologists, and are given guidance and mentorship to realize their individual professional goals and aspirations.
The program leadership, comprised of all executive fellowship hematology-oncology faculty and the program director, provide continual oversight of the program and its trainees.
Curriculum
PGY-4
| Rotation | Req/Elec | Duration* | Description |
|---|---|---|---|
| Breast Oncology | Required | 1 month | 100% outpatient; Continuity clinic 2x week |
| Thoracic Oncology | Required | 1 month | 100% outpatient; Continuity clinic 2x week |
| Inpatient Hematology | Required | 3 months | 80% inpatient; Continuity clinic 2x week |
| Elective | Elective | 1 month | 100% outpatient; Continuity clinic 2x week |
| Inpatient Oncology | Required | 1 months | 80% inpatient; Continuity clinic 2x week |
| Oncology Consults | Required | 2 months | 80% inpatient; Continuity clinic 2x week |
| BMT | Required | 1 month | 50% inpatient, 50% outpatient; Continuity clinic 2x week |
| GI Oncology | Elective | 1 month | 100% inpatient; Continuity clinic 2x week |
| Benign Hematology | Required | 1 month | 80% inpatient, 20% outpatient; Continuity clinic 2x week |
PGY-5
| Rotation | Req/Elec | Duration* | Description |
|---|---|---|---|
| Transfusion/Hemepath | Required | 1 month | 100% outpatient; Continuity clinic 2x week |
| Breast Oncology | Elective | 1 month | 100% outpatient; Continuity clinic 2x week |
| Sarcoma | Required | 1 month | 100% outpatient; Continuity clinic 2x week |
| Inpatient Hematology | Required | 1 month | 80% inpatient; Continuity clinic 2x week |
| Oncology Consults | Required | 1 month | 80% inpatient; Continuity clinic 1x week |
| Research/Elective | Elective | 3 months | 100% inpatient; Continuity clinic 2x week |
| Benign Hematology | Required | 2 month | 80% inpatient; Continuity clinic 1x week |
| Melanoma | Required | 1 months | 100% outpatient; Continuity clinic 2x week |
| Thoracic Oncology | Required | 1 month | 100% outpatient; Continuity clinic 2x week |
PGY-6
| Rotation | Req/Elec | Duration* | Description |
|---|---|---|---|
| Benign Hematology | Required | 1 month | 80% inpatient, 20% outpatient; Continuity clinic 2x week |
| Oncology Consults | Required | 1 month | 80% inpatient; Continuity Clinic 2x week |
| Breast Oncology | Elective | 1 month | 100% outpatient; Continuity clinic 2x week |
| Thoracic Oncology | Elective | 1 month | 100% outpatient; Continuity clinic 2x week |
| GI/Neuro-Oncology | Elective | 1 month | 100% outpatient; Continuity clinic 2x week |
| Research/Elective | Required | 6 months | Continuity clinic 2x week |
| Inpatient Hematology | Required | 1 month | 100% inpatient; Continuity clinic 2x week |
Our Team
Message From Our Director
On behalf of Houston Methodist Division of Hematology and Oncology, I would like to thank you for your interest in our Hematology and Oncology Fellowship. I would like to share with you a brief overview of the program. The division of hematology and oncology at Houston Methodist Hospital has undergone a significant growth in the past decade and is composed of physicians and physician scientists that cover the breadth of hematology and medical oncology. Our vigorous clinical trials program offers innovative therapies to patients.
The goal of our fellowship is to train outstanding clinicians, clinician-scientists and translational researchers in hematology and oncology. The fellowship program enjoys a wealth of diverse clinical expertise and patient variety for hematology oncology. A broad and deep exposure to the clinical problems is made possible by two half-day continuity clinics a week for specialty general hematology and oncology.
The continuity clinics are staffed by the subspecialty faculty enhancing the learning experience. The fellows follow their own panel of patients throughout their training, greatly enhancing the clinical experience. The fellow’s clinic is supported by a medical assistant as well as a nurse. The hematology rotations include malignant hematology inpatient and outpatient, benign hematology rotation, bone marrow transplant rotation, transfusion and hematopathology rotation and a procedure rotation. The oncology rotations include outpatient breast, thoracic, GI, neuro-oncology, gynecology, sarcoma, melanoma, palliative care and radiation oncology.
In addition, fellows go to Legacy Clinic, federally qualified health center (FQHC) once a month to see variety of benign hematologic to oncologic metastatic disease in underserved population. Starting July 2019, Fellows will also be rotating to Ben Taub and Smith Clinic for part of their continuity clinic rotation.
Research is a required part of fellowship. The fellowship can be structured so that up to 12 months of the 36 months fellowship can be devoted to the research. A variety of research opportunities including laboratory-based research, big data mining and clinical and translational research are available. The mentorship committee includes a biostatistician, clinical researcher, and multiple translational researchers. In 2019, we are proud to have two fellows win the ASCO Merit award, one fellow win ASCO SITC merit award and two fellows chosen to participate at ASCO Vail workshop.
To facilitate exposure to various hematology oncology meetings, the first year fellows attend ASH annual meeting, the second year fellows attend San Antonio Breast cancer symposium and ASCO annual meeting. The third year fellows attend a board review course. In addition, they can attend additional meetings when presenting.
Our division is a close group. The faculty are friendly, approachable and committed to the fellowship and fellow’s education.
We appreciate your interest and look forward to meeting you.
-Hanh Mai P. Mai, DO MSMS
Program Director: Hanh P. Mai, DO MSMS
Associate Program Director: Lawrence Rice, MD
Associate Program Director: Jun Zhang, MD
Houston Methodist Dr. Mary and Ron Neal Cancer Center Director: Jenny Chang, MD
Program Coordinator: Sandra Soliz
Executive Fellowship Committee
Hematology Oncology Faculty
- Maen Abdelrahim, MD
- Anna Belcheva, MD
- Ethan Burns, MD
- Jenny Chang, MD
- Eleni Efstathiou, MD
- Siddhartha Ganguly, MD
- Kirk Heyne, MD
- Dharamvir Jain, MD
- Ryan Kieser, MD
- Hanh Mai, MD
- Anaum Maqsood, MD
- Asha Murthy, MD
- Sindhu Nair, MD
- Polly Niravath, MD
- Ravi Pingali, MD
- Priya Ramshesh, MD
- Shilpan Shah, MD
- Monisha Singh, MD
- Kai Sun, MD
- Carrie H. Yuen, MD
- Jun Zhang, MD
BMT Faculty (Baylor College of Medicine/Texas Children's Hospital)
- Malcolm Brenner, MD
- George Carrum, MD
- Helen Heslop, MD
- LaQuisa Hill, MD
- Ram Kamble, MD
- Robert Krance, MD
- Premal Lulla, MD
- Carlos Ramos, MD
Eligibility and Application
Fellowship application and required documentation must be submitted through the Electronic Residency Application Service (ERAS).
The documentation listed below must be submitted with the application:
Application Requirements
- Official medical school transcript in original language and in English (copied and notarized, stating that it is a true copy of the original)
- Three letters of recommendation plus a letter of recommendation from your program director
- Personal statement
- Curriculum vitae
- USMLE/COMLEX Scores (must possess a passing score)
- Photograph
Houston Methodist is committed to improving the health of our patients, employees, and communities around us. As a health care provider, it’s our responsibility to promote a healthier environment for our employees.
Responsibility
- Drug and Tobacco Screening- Job seekers will be tested for nicotine and drug usage during the post-offer physical. If a job seeker tests positive for nicotine use, including nicotine gum and patches, the offer will be rescinded, and individuals will be given the opportunity to participate in a free Houston Methodist-provided tobacco cessation program. Job seekers wishing to reapply after testing positive for nicotine may do so 90 days after the date the initial offer was rescinded. If the job seeker tests positive for drug use, the offer will be rescinded. Job seekers wishing to reapply after the drug screening is positive may do so one year after the date the initial offer was rescinded.
- Background Check - Prior to employment start date, job seekers must complete a criminal background check.
Research
Our Milestones
- 2022 Fellow of the Year Houston Methodist Neal Cancer Canter Hematology Oncology Fellowship
- Ryan Kieser, MD
- 2022 Abstract Achievement Award, Houston Methodist Cancer Center Symposium
- Ethan Burns, MD
- 2022 Wadi Suki Foundation community Scholar Award
- Ethan Burns, MD
- 2022 Jerold B. Katz Foundation’s Houston Methodist 2022 Humanitas Award
- Ethan Burns, MD
- 2022 Houston Methodist Cancer Center Nurses’ Choice Award
- Ethan Burns, MD
- 2022 FDA/ASCO Fellows’ Day Workshop
- Zimu Gong, MD
- 2022 Research Award of Excellence Houston Methodist Neal Cancer Center Hematology Medical Oncology Fellowship
- Kai Sun, MD
- 2022 ASCO Conquer Cancer Foundation Young Investigator Award
- Kai Sun, MD
- 2021 Research Award of Excellence Houston Methodist Neal Cancer Center Hematology Medical Oncology Fellowship
- Kai Sun, MD
- 2021 Fellow of the Year Houston Methodist Neal Cancer Center Hematology Medical Oncology Fellowship
- Kai Sun, MD
- 2021 Nurses’ Choice Award Houston Methodist Hospital
- Ethan A. Burns, MD
- 2021 AACR/ACO Vail Recipient
- Kai Sun, MD
- 2021 ASCO Merit Award
- Kai Sun, MD
- 2021 ASCO/FDA Fellow’s Clinical Workshop
- Kai Sun
- 2021 Burroughs Wellcome Fund Fellow
- Kai Sun, MD
- 2021 ASCO Conquer Cancer Merit Award
- Carlo Guerrero, MD
- Akshjot Puri, MD
- 2020 ASCO Advocacy Summit
- Abeer Arain, MD
- 2020 Research Award of Excellence Houston Methodist Cancer Center Hematology Medical Oncology Fellowship
- Akshjot Puri, MD
- 2020 Fellow of the Year Houston Methodist Cancer Center Hematology Medical Oncology Fellowship
- Kai Sun, MD
- 2020 Nurses’ Choice Award Houston Methodist Hospital
- Carlo Guerrero, MD
- 2019 Research Award of Excellence Houston Methodist Cancer Center Hematology Medical Oncology Fellowship
- Kartik Anand, MD
- 2019 Fellow of the Year Houston Methodist Cancer Center Hematology Medical Oncology Fellowship
- Cesar Gentille, MD
- 2019 Nurses’ Choice Award Houston Methodist Hospital
- Sarah Lynn Creamer, MD
- ASCO/FDA Fellow’s Clinical Workshop. November, 2020. Silver Springs, MD
- Akshjot Puri, M.D.
- ICML International Conference of Malignant Lymphoma (Switzerland):
- Kartik Anand M.D.: Comprehensive report of anti-CD19 chimeric antigen receptor T-cells (CAR-T) associated Non Relapse Mortality (CART-NRM) from FAERS
- ASCO 2019
- Emre Koca M.D.: Phase II Trial Of Neoadjuvant TAK-228 Plus Tamoxifen In Patients With (ER)-Positive, HER2-Negative Breast Cancer. MERIT AWARD
- Kartik Anand M.D.: Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. MERIT AWARD
- Kartik Anand M.D. Neoadjuvant Phase II study of Everolimus plus Cisplatin in TNBC patients with Residual Disease
- ASCO-SITC (Society of Immunotherapy of Cancer) 2019
- Kartik Anand M.D.: T-cell lymphoma secondary to CPI use for other malignancies. MERIT AWARD
- Houston Methodist Cancer Symposium 2018
- Sarah Creamer M.D.: Best clinical Trial Poster Award
- Texas ASCO 2018
- Emre Koca M.D.: Association of PRAME expression with clinical features in uveal melanoma ($1000 Award)
2019 ASCO Vail Recipients
- Emre Koca M.D. Phase I study of autologous T lymphocytes expressing GD2-specific chimeric antigen treatment of patients with pre-treated metastatic uveal melanoma patients.
- Akshjot Puri M.D. Neurocognitive and Neuroimaging Assessments in Investigating the Mechanism of Cancer-Related Cognitive Impairment in Breast Cancer
Our Publications
-
Kai Sun, Yitian Xu, Licheng Zhang, Eric H. Bernicker, Jenny C. Chang, et al. A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-22-0622.
-
Xiangliang Yuan, Yimin Duan, Yi Xiao, Kai Sun, Dihua Yu et al. Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. Cancer Discov. 2022 Apr 14; candisc.0900.2021. doi: 10.1158/2159-8290.CD-21-0900. Pubmed ID: 35420681.Impact factor 39.4.
-
Kai Sun, Charisma Mylavarapu, Aubrey Crenshaw, Yuqi Zhang, Enshuo Hsu, Jiaqiong Xu, Marilyn Niravath, Juan Carlos Nicolas, Stephen Jones, Adriana Ordonez, Maen Abdelrahim. Pancreatic head versus pancreatic body/tail cancer: are they different? World J Gastrointest Oncol. March 15,2022;14(3);716-723. Doi: 10.4251/wjgo.v14.i3.716. Pubmed ID: 35321276.
-
Guo M, Liu J, Miao R, Ahmed Z, Yu J, Guan J, Ahmad S, Zhou S, Grove A, Manoucheri M, Socinski MA, Mekhail T. A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. J Immunother. 2022 Sep 5. doi: 10.1097/CJI.0000000000000440. Epub ahead of print. PMID: 36066505.
-
Tao L, Miao R, Mekhail T, Sun J, Meng L, Fang C, Guan J, Jain A, Du Y, Allen A, Rzeszutko BL, Socinski MA, Chang CC. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2021 Jul;22(4):e506-e511. PMID: 32807653.
-
Mylavarapu C, Lu AJ, Burns EA, Samorajski J, Gotur D, Baker K. Diffuse Cerebral Edema and Impending Herniation Complicating Hepatic Encephalopathy in Hereditary Hemorrhagic Telangiectasia. Case Rep Med. 2022 Feb 18;2022:2612544. doi: 10.1155/2022/2612544. PMID: 35222647
-
Chitturi KR, Burns EA, Muhsen IN, Anand K, Trachtenberg BH. Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. Curr Oncol Rep. 2022 Apr;24(4):475-491. doi: 10.1007/s11912-022-01215-Epub 2022 Feb 22. PMID: 35192115.
-
Burns EA, Ensor JE, Hsu J, Thomas JS, Olsen RJ, Bernicker EH. Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience. J Thorac Dis. 2021 Aug;13(8):4785- 4796. doi: 10.21037/jtd-21-432. PMID: 34527319 13.
-
Hsu J, Annunziata JF, Burns EA, Bernicker EH, Olsen RJ, Thomas JS. Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status. Clin Pathol. 2022 May 23;15:2632010X221102054. doi: 10.1177/2632010X221102054. PMID: 35634237; PMCID: PMC9134433.
- Sarfraz H, Gentille C, Ensor J, Wang L, Wong S, Ketcham MS, Joshi J, Pingali SRK. Primary cutaneous anaplastic large-cell lymphoma: a review of the SEER database from 2005 to 2016 Clin Exp Dermatol. 2021 Jun 3. doi: 10.1111/ced.14777. Online ahead of print.PMID: 34081802
- Puri A, Chang J, Tanner N, Lucente P, Desiongco J, Dragovich T, Naraev B, Kundranda M. Skeletal metastases in advanced pancreatic ductal adenocarcinoma (PDAC): A retrospective analysis. J Gastrointestin Oncol. 2021 Apr; 12(2): 455-463
- Melissa Yan, Ryan Kieser, Carol C. Wu, Wei Qiao, Cristhiam M. Rojas-Hernandez; Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. Blood Adv 2021; 5 (4): 1050–1058. doi: https://doi.org/10.1182/bloodadvances.2020003136
- Sarfraz H, Arain A, Divatia MK, Schwartz MR, Heyne KE. Metastatic colorectal carcinoma to the right atrium: a case report and review of the literature. Cardiooncology. 2021 May 31;7(1):21. doi: 10.1186/s40959-021-00108-9. PMID: 34059136; PMCID: PMC8165980.
- Mina SA, Muhsen IN, Burns EA, Sarfaraz H, Pingali SR, Xu J, Hashmi SK. Post-Marketing Analysis of Peripheral Neuropathy Burden with Newer Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System (FAERS). Turk J Haematol. 2021 Jun 30. doi: 10.4274/tjh.galenos.2021.2021.0052
- Yu KH, Hendifar AE, Alese OB, Draper A, Abdelrahim M, Burns EA, Khan G, Cockrum P, Bhak RH, Nguyen C, DerSarkissian M, Duh MS and Bahary N. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Front. Oncol. 2021;11:678070. doi: 10.3389/fonc.2021.678070
- Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases. 2021; 9(1):20. https://doi.org/10.3390/diseases9010020
- Burns EA, Koca E, Xu J, McLean E, Lee R, Patel T, Chang J, Niravath P. Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy. Oncologist. 2021 Feb 16;. doi: 10.1002/onco.13722.
- Burns EA, Muhsen IN, Anand K, Xu J, Umoru G, Arain AN, Abdelrahim M. Hepatitis B Virus Reactivation in Cancer Patients Treated with Immune Checkpoint Inhibitors. J Immunother. 2021 Jan 19. doi: 10.1097/CJI.0000000000000358
- Kai Sun, Humaira Sarfraz, Maen Abdelrahim. Complete response of metastatic pancreatic cancer in a CHEK2 mutation carrier treated with platinum-based therapy- A case report and literature review. Br J Gastroenterol. 2020;2(4): 194-198.doi: 10.31488/bjg.1000121.
- Anand K, Sahu G, Burns EA, Ensor A, Ensor J, Pingali SR, Subbiah V, Iyer SP. Mycobacterial Infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open 2020;5:e000866. doi: 10.1136/esmoopen-2020-000866
- Burns EA, Abdelrahim M. The Rising Tide of Pancreatic Adenocarcinoma: A Review of Risk Factors, Diagnostic Challenges, and Treatment Updates. J Cancer Biol. 2020; 1(2): 23-27\
- Kasparian S, Burns EA, Shehabeldin A, Awar M, Pingali SR. Recurrent Small Bowel Obstruction Caused by Burkitt Lymphoma. J Med Case Rep. 2020 Aug 12;14(1):127. doi: 10.1186/s13256-020-02449-y.
- Kasparian S, Gentille C, Burns EA, Bernicker H. Hyperprogressive non-small cell lung cancer with two immune checkpoint inhibitors. JTO Clinical and Research Reports. 2020: 1; 2, 100017.
- Arain A, Muhsen IN, Abdelrahim M. Acquired haemophilia as a paraneoplastic manifestation of pancreatic cancer. Ecancermedicalscience. 2020 Jun 4;14:1053. doi: 10.3332/ecancer.2020.1053. PMID: 32582368; PMCID: PMC7302889.
- Arain A. Smoking among breast cancer survivors. Breast J. 2020 Dec;26(12):2452-2453. doi: 10.1111/tbj.14107. Epub 2020 Nov 28. PMID: 33248446.
- Puri A, Kamble RT, Pingali SR. Individualizing Approach to Primary CNS Lymphoma. Diagnosis and Treatment: Hematology Journal. 2020 (1): 23-32. 10.33513/DTHJ/2001-03
- Gentille C, Anand K, Dalwadi S, Puri A, Farach A, Pingali SR. Radiation therapy in primary mediastinal large B-cell lymphoma treated with DA-R-EPOCH Clin Case Rep. 2020 Apr 13;8(7):1153-1155. doi: 10.1002/ccr3.2853. eCollection 2020 Jul.PMID: 32695347
- Mooneyham J, Gentille C, Barbieri A, Shah S. Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement BMJ Case Rep. 2020 Sep 7;13(9):e235412. doi: 10.1136/bcr-2020-235412.PMID: 32900727
- Guerrero C, Jain T, Kelemen K. HHV-8-Associated Lymphoproliferative Disorders and Pathogenesis in an HIV-Positive Patient.
Case Rep Hematol. 2019;2019:4536157. Published 2019 Aug 22. doi:10.1155/2019/4536157 - Puri A, Reddy T, Patel TA, Chang JC. Metastatic triple negative breast cancer: Established and Emerging Treatments. The breast journal. In Press
- Puri A, Kamble RT, Pingali SR. Individualizing Approach to Primary CNS Lymphoma. Diagnosis and Treatment: Hematology journal. In Press
- Kai Sun, Ryan J Reynolds, Tiffany G Sheu, Jessica A Thomsula, Laura Colton, Lawrence Rice. Acute myeloid leukemia presenting as acute liver failure- a case report and literature review.
Ecancermedicalscience. 2019 Sep 9; 13:960. https://doi.org /10.3332/ecancer.2019.960. Pubmed ID: 31645888 - Gentille C, Anand K, Dalwadi S, Puri A, Farach A, Pingali S. Radiation therapy in primary mediastinal large B‐cell lymphoma treated with DA‐R‐EPOCH.
Clinical case reports. 2020 April; doi: https://doi.org/10.1002/ccr3.2853. - Kasparian S, Gentille C, Burns E, Bernicker EH. Hyperprogressive non-small cell lung cancer with two immune-checkpoint inhibitors.
JTO Clinical and Research Reports. 2020 February; doi: https://doi.org/10.1016/j.jtocrr.2020.100017 - Burns EA, Gentille C, Kasparian S, Pingali SR. A Case of Histiocytic Sarcoma Arising from Mycosis Fungoides.
Case Rep Hematol. 2019;2019:7834728. doi: 10.1155/2019/7834728. eCollection 2019. PubMed PMID: 31687231; PubMed Central PMCID: PMC6794960 - Schefler A, Koca E, Bernicker E, Correa Z. Relationship between clinical features, GEP class and PRAME expression in uveal melanoma. Graefe’s Archive for clinical and experimental opthomology. 2019; 1-5.
- Anand K, Kumar P, Pingali SR et al. Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeerminate potential. Am J Hematol 2019; 94: E82-E85.
- Anand K, Niravath P. Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia. Curr Oncol Rep 2019; 21: 51.
- Anand K, Ibrahim I. Four Limb Ischemia: A Severe Case of Heparin Induced Thrombocytopenia. Indian J Hematol Blood Transfus 2019; 35: 397-398.
- Burns E, Anand K, Acosta G et al. Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH). Case Rep Hematol 2019; 2019: 3146965.
- Wallis CJ, Satkunasivam R, Butaney M, Khan UA, Goldberg HA..Klaassen et al. Association between smoking and survival benefit of immunotherapy in advanced malignancies: A systemic review and meta-analysis. American Journal of Cliniacl Oncology 2019 September; 42(9): 711-716
- Patel, TA, Ensor JE, Creamer SL, Boone T..Chang JC. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2 positive breast cancer (TEAL study). Breast cancer research 2019 Sept 2; 21(1):100
- Kasparian S, Anand K, Burns E, Chung B, Pingali SRK. Macrophage Activation Syndrome Secondary to Underlying Sarcoidosis. 2019 Jun 18; 11(6)
- Anand K, Roszik J, Hall C…Patel S. Pilot Study of Circulating Tumor cells in Early Stage and Metastatic Uveal Melanoma. Cancers (Basel). 2019 Jun 20; 11(6)
- Anand K, Pingali SR, Trachtenberg B, Iyer SP. Complete Response to R-EPOCH in Primary Cardiac Lymphoma. Case R Hematology 2019 April 10.
- Anand, K, Ibrahim I. Four Lim Ischemia: A severe case of Heparin Induced Thrombocytopenia. Indian J Hematology Blood Transfusion 2019 April
Our Fellows
Shubham Adroja, MD - PGY6
Cleveland Clinic Akron General
Akron, OH
Akron, OH
Zainub Ajmal, MD - PGY6
Albany Medical Center
Albany, NY
Albany, NY
Yuan Gao, MD - PGY6
Baylor University Medical Center in Dallas
Dallas, TX
Dallas, TX
Vikram Dhillon, DO, MBA - PGY5
Wayne State University
Detroit Medical Center
Detroit, MI
Detroit Medical Center
Detroit, MI
Akhil Mehta, DO, MPH - PGY5
Loma Linda University Medical Center
Loma Linda, CA
Loma Linda, CA
Yuqi Zhang, MD, PhD - PGY5
Houston Methodist Hospital
Houston, TX
Houston, TX
Kelly Gee, DO - PGY3
Houston Methodist Hospital
Houston, TX
Houston, TX
Nicholas Spetsieris, MD - PGY3
Long Island Community Hospital Program
Patchogue, NY
Patchogue, NY
Catherine Wiechmann, MD - PGY3
Houston Methodist Hospital
Houston, TX
Houston, TX
Our Alumni
|
Class of 2024 Jian Guan, MD, PhD
Class of 2023 |
Class of 2022 Abeer Arain, MD Hematology-Oncology St. Joseph Regional Medical Center Lewiston, ID Carlo Guerrero, MD Oncologist HonorHealth Virginia G. Piper Cancer Center Scottsdale, AZ Kai Sun, MD Breast Oncologist Houston Methodist Hospital Houston, TX Class of 2021 Cesar Gentille, MD Assistant Professor of Medicine Division of Hematology, Stem Cell Transplantation & Cellular Therapy University of Arkansas for Medical Sciences Little Rock, AR Akshjot Puri, MD Hematology Oncology Our Lady of Lourdes Regional Medical Center Lafayette, LA |
Class of 2020 Class of 2019 |
Class of 2018 Class of 2017 |
Get In Touch
Fellowship Coordinator
Program Director
Hanh P. Mai, DO MSMS
Houston Methodist Dr. Mary and Ron Neal Cancer Center
6445 Fannin, OPC-24
Houston, Texas 77030
Houston Methodist Dr. Mary and Ron Neal Cancer Center
6445 Fannin, OPC-24
Houston, Texas 77030
Upcoming Academic Events
Grand rounds, tumor boards, regularly scheduled series and case presentations are offered in multiple clinical disciplines and Houston Methodist locations.
Renal Grand Rounds - Richard J. Glassock, MD
Richard J. Glassock, MD, MACP, FRCP (London), FASN
Jan 09 @ 12PM
See Details
55
Grand Rounds conducted in 2023
These educational events are held according to varying schedules by departments and divisions within the Houston Methodist Academic Institute
Donate to Houston Methodist
With your support, Houston Methodist provides exceptional research, education, and care that is truly leading medicine.
Donate Now